argenx SE is a commercial-stage biopharma company developing therapies for autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. It offers VYVGART for gMG and immune thrombocytopenia, and VYVGART HYTRULO for gMG and CIDP, while developing efgartigimod, empasiprubart, adimanebart and other candidates, with partners including Zai Lab, Halozyme Therapeutics, OncoVerity and AbbVie.